This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 11
  • /
  • SAR 153191 (sarilumab) BLA is filed at FDA to trea...
Drug news

SAR 153191 (sarilumab) BLA is filed at FDA to treat rheumatoid arthritis- Regeneron + Sanofi

Read time: 1 mins
Last updated:6th Nov 2015
Published:6th Nov 2015
Source: Pharmawand

At announcement of Q3 earnings Regeneron noted that a biologics license application (BLA) for sarilumab (SAR 153191) to treat rheumatoid arthritis was recently submitted to the FDA.

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news
Complete Response from FDA for dasiglucagon to prevent and treat congenital hypoglycemia

Zealand Pharma A/S announced that the FDA has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing

1 mins
Drug news
Keytruda (pembrolizumab) met primary endpoint of event-free survival (EFS) as perioperative treatment regimen in patients with resected, locally advanced head and neck squamous cell carcinoma

The study evaluated Keytruda as neoadjuvant therapy, then continued after surgery in combination with standard-of-care radiotherapy (with or without cisplatin) as adjuvant therapy, followed by Keytruda as maintenance therapy, compared to adjuvant radiotherapy (with or without cisplatin) alone

2 min
Drug news
Positive data for Arexvy, respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons

GSK plc  announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older, including those at increased risk over three full RSV seasons (NCT04886596)

1 min
See all news